TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11059520

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoid therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic glucocorticoid therapy
Number of subjects: 0
Study: 8874677

Group type: EXPERIMENTAL
Intervention: Qigong training
Number of subjects: 0
Study: 1412754

Group type: EXPERIMENTAL
Intervention: Double therapy with cyclosporine and prednisolone
Number of subjects: 463

Group type: COMPARATOR
Intervention: Triple therapy with cyclosporine, azathioprine, and prednisolone
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Double therapy with cyclosporine and prednisolone (subgroup with azathioprine)
Number of subjects: 463
Study: 3927371

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 0
Study: 30474791

Group type: EXPERIMENTAL
Intervention: IV ibuprofen (800 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IV paracetamol (1000 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (100 ml saline solution)
Number of subjects: 90
Study: 30485422

Group type: EXPERIMENTAL
Intervention: Adherence intervention for patients not taking DMT due to avoidance reasons
Number of subjects: 78
Study: 28412755

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (group S, n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous propofol anesthesia (group P, n = 25)
Number of subjects: 50
Study: 26037276

Group type: EXPERIMENTAL
Intervention: Active video games (AVG) for 16 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal activities (NAG) for 16 weeks
Number of subjects: 21
Study: 24246616

Group type: EXPERIMENTAL
Intervention: rabeprazole (20mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: omeprazole (20mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 21677059

Group type: EXPERIMENTAL
Intervention: 4% l-arabinose in sucrose beverages
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (0% l-arabinose in sucrose beverages)
Number of subjects: 15
Study: 19111776

Group type: EXPERIMENTAL
Intervention: Vertical motion in the same direction as the oblique motion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vertical motion in the opposite direction to the oblique motion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased speed of vertical motion
Number of subjects: 0
Study: 16952809

Group type: EXPERIMENTAL
Intervention: Perineural space expansion with 10 mL dextrose 5% in water (D5W) flush before catheter placement
Number of subjects: 60

Group type: COMPARATOR
Intervention: No perineural space expansion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Perineural space expansion
Number of subjects: 60
Study: 15291224

Group type: EXPERIMENTAL
Intervention: Singer's Five‐step Strategy introduced prior to starting acquisition trials (100% group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Singer's Five‐step Strategy introduced after acquisition Trial Block 1 (83% group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Singer's Five‐step Strategy introduced after acquisition Trial Block 3 (50% group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Singer's Five‐step Strategy introduced after acquisition Trial Block 5 (17% group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (0% group)
Number of subjects: 50
Study: 11293457

Group type: EXPERIMENTAL
Intervention: Yes-no task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forced-choice task
Number of subjects: 0
Study: 9444798

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid a‐IFN (3MU i.m. every two days for 2 months, then 6MU i.m. every second two days for additional 10 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-specific support therapy (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid a‐IFN
Number of subjects: 100
Study: 7942533

Group type: EXPERIMENTAL
Intervention: 81 mg aspirin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 162 mg aspirin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 324 mg aspirin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All doses of aspirin (81, 162, 324 mg)
Number of subjects: 18
Study: 3203047

Group type: EXPERIMENTAL
Intervention: Inhaled ouabain (1 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29893977

Group type: EXPERIMENTAL
Intervention: Shoulder Movement Intervention (ShoMo)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Wellness Intervention
Number of subjects: 52
Study: 27585484

Group type: EXPERIMENTAL
Intervention: Visual search training
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Dot-probe training
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo control conditions
Number of subjects: 340
Study: 25146059

Group type: EXPERIMENTAL
Intervention: Acupressure with essential oils
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Acupressure only
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Acupressure with or without essential oils
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 57
Study: 23742676

Group type: COMPARATOR
Intervention: Subclinical hyperthyroidism (group II)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Overt hyperthyroidism (group III)
Number of subjects: 93
Study: 21283156

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (Zymar) and masked dexamethasone 0.1% (Maxidex)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gatifloxacin (Zymar) and a masked placebo
Number of subjects: 30
Study: 20058619

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (non-metformin)
Number of subjects: 140
Study: 16498000

Group type: EXPERIMENTAL
Intervention: One-stage procedure
Number of subjects: 168

Group type: COMPARATOR
Intervention: Two-stage procedure
Number of subjects: 168
Study: 15799920

Group type: EXPERIMENTAL
Intervention: Totally endoscopic approach
Number of subjects: 17

Group type: COMPARATOR
Intervention: Minithoracotomy group
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Totally endoscopic group
Number of subjects: 17
Study: 10917406

Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (1 mg single dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (1 mg/day for 6 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desacetyl-alpha-MSH (equimolar doses)
Number of subjects: 60
Study: 9293327

Group type: EXPERIMENTAL
Intervention: Clean prep kits
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sterile prep kits
Number of subjects: 60
Study: 8101304

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (short periods of ischaemia with intermittent reperfusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of adenosine triphosphate in biopsy specimens
Number of subjects: 0
Study: 3582518

Group type: EXPERIMENTAL
Intervention: Theophylline therapy (5 days oral administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30766567

Group type: EXPERIMENTAL
Intervention: PASCAL laser
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional laser
Number of subjects: 28
Study: 27557705

Group type: EXPERIMENTAL
Intervention: Brief case management for 4 to 6 months
Number of subjects: 166

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 166
Study: 26573809

Group type: EXPERIMENTAL
Intervention: Educational materials plus coach training (COACH)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Printed educational materials only (PEM)
Number of subjects: 2
Study: 22990943

Group type: EXPERIMENTAL
Intervention: Escitalopram or Nortriptyline
Number of subjects: 108
Study: 16184460

Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg/day)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 176
Study: 12847070

Group type: EXPERIMENTAL
Intervention: Tenecteplase + Enoxaparin (30 mg IV bolus followed by 1 mg/kg SC BID for 7 days)
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: Tenecteplase + Enoxaparin
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Tenecteplase + Unfractionated Heparin (UFH)
Number of subjects: 1639
Study: 9741753

Group type: EXPERIMENTAL
Intervention: Imagery-type words
Number of subjects: 25

Group type: COMPARATOR
Intervention: Abstract-type words
Number of subjects: 25
Study: 7793887

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg daily oral doses for at least 3 weeks
Number of subjects: 4
Study: 2338029

Group type: EXPERIMENTAL
Intervention: Intravenous S/A (1.0/2.0 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous S/A (0.5/1.0 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intramuscular S/A (0.5/1.0 g)
Number of subjects: 10
Study: 380913

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg once daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Indomethacin (25 mg 3-times daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ibuprofen (400 mg 3-times daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29771148

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous needle electrolysis (n = 39)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo puncture (n = 34)
Number of subjects: 73
Study: 27733180

Group type: EXPERIMENTAL
Intervention: linagliptin (5 mg) administered once daily for 12 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 25675797

Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF) after regional anesthesia (n=49)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF) after general anesthesia (n=48)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine oral feeding (ROF) after regional anesthesia (n=47)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine oral feeding (ROF) after general anesthesia (n=48)
Number of subjects: 200
Study: 23867008

Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Flexible outpatient clinic appointments
Number of subjects: 1000
Study: 20392575

Group type: EXPERIMENTAL
Intervention: TAU plus CBT4CBT
Number of subjects: 77

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 77
Study: 18191416

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (monotherapy)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 162
Study: 15679698

Group type: EXPERIMENTAL
Intervention: Oral eletriptan 80 mg
Number of subjects: 311

Group type: COMPARATOR
Intervention: Subcutaneous sumatriptan 6 mg (suma-sc)
Number of subjects: 311
Study: 12091866

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) once per week for 6 weeks + 6 sessions of cognitive-behavioral treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) 3 times per week for 6 weeks + 6 sessions of cognitive-behavioral treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 10346773

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 501
Study: 9816048

Group type: EXPERIMENTAL
Intervention: Carboxyamido-triazole (CAI) liquid formulation at doses of 100, 125, and 150 mg/m2/day and 200 and 330 mg/m2 every other day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Carboxyamido-triazole (CAI) gelcap formulation at doses of 100 and 125 mg/m2/day and 200 mg/m2 every other day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Carboxyamido-triazole (CAI)
Number of subjects: 39
Study: 1675316

Group type: EXPERIMENTAL
Intervention: Propranolol (20-160 mg twice daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 54
Study: 7449302

Group type: EXPERIMENTAL
Intervention: Propranolol (average daily dose 240 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Untreated group (Control)
Number of subjects: 55
Study: 31528865

Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allograft with collagen wound dressing (test 2 group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Collagen wound dressing alone (control group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allograft with dense polytetrafluoroethylene membrane (test 1 group)
Number of subjects: 21
Study: 28176302

Group type: EXPERIMENTAL
Intervention: Educare
Number of subjects: 239

Group type: COMPARATOR
Intervention: Business-as-usual control group
Number of subjects: 239
Study: 25957440

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23357561

Group type: EXPERIMENTAL
Intervention: Multi-level stepped intervention to increase CRC screening rates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21249417

Group type: EXPERIMENTAL
Intervention: Physical and educational intervention (Group 1) consisting of relaxation and posture exercises and the use of visual feedback.
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control group (Group 2) received the same intervention after 6 months.
Number of subjects: 384
Study: 18620344

Group type: EXPERIMENTAL
Intervention: Right lateral position (RLP) after swallowing the capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-right lateral position (standing up position)
Number of subjects: 0
Study: 17030153

Group type: EXPERIMENTAL
Intervention: AudioScope screening
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: HHIE-S screening
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: Combined screening (AudioScope + HHIE-S)
Number of subjects: 2305

Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 2305
Study: 15129412

Group type: EXPERIMENTAL
Intervention: Gait retraining with the FDHO model
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gait retraining with the PSF
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 16
Study: 11461943

Group type: COMPARATOR
Intervention: L-NAME + Placebo (PL)
Number of subjects: 7

Group type: COMPARATOR
Intervention: L-NAME + Losartan (LOS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: L-NAME + Indomethacin (IND)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: L-NAME + Indomethacin + Losartan (IND + LOS)
Number of subjects: 7
Study: 9712594

Group type: EXPERIMENTAL
Intervention: Postcoital test included in infertility investigations
Number of subjects: 444

Group type: COMPARATOR
Intervention: Control group (series excluding the postcoital test)
Number of subjects: 444
Study: 7978092

Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 g/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ethanol 0.9 g/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (Ethanol 0.0 g/kg)
Number of subjects: 10
Study: 2532682

Group type: EXPERIMENTAL
Intervention: cyclobenzaprine
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 1203854

Group type: EXPERIMENTAL
Intervention: POMP (prednisolone, vincristine, methotrexate, and 6-mercaptopurine)
Number of subjects: 73

Group type: COMPARATOR
Intervention: VP (vincristine and prednisone)
Number of subjects: 73
Study: 29175569

Group type: EXPERIMENTAL
Intervention: Low-dose tranexamic acid (10 mg/kg loading dose, then 1 mg·kg‐1·hr‐1 throughout surgery)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 28332888

Group type: EXPERIMENTAL
Intervention: Home self‐collected HPV testing
Number of subjects: 1769

Group type: COMPARATOR
Intervention: Clinician‐collected Pap screening
Number of subjects: 1769

Group type: EXPERIMENTAL
Intervention: Self‐collected HPV test recommendation by clinicians
Number of subjects: 1769
Study: 26160625

Group type: EXPERIMENTAL
Intervention: Twice-daily administration of perindopril (4 mg morning and 4 mg evening)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Twice-daily administration of losartan (50 mg morning and 50 mg evening)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Once-daily evening administration of perindopril (8 mg)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Once-daily evening administration of losartan (100 mg)
Number of subjects: 164
Study: 23293945

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin G (generic formulation, 1,200,000 IU)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Retarpen® 1.2 million units (innovator's product)
Number of subjects: 12
Study: 20841410

Group type: EXPERIMENTAL
Intervention: vitalHEAT system (circulating-water sleeve on 1 arm)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Forced air warming cover (upper-body)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Comparison of vitalHEAT to forced air
Number of subjects: 71
Study: 17387314

Group type: EXPERIMENTAL
Intervention: 2-h arm crank ergometer exercise at 60% of VO(2max)
Number of subjects: 13
Study: 16198030

Group type: COMPARATOR
Intervention: Female athletes during medial drop landing
Number of subjects: 22

Group type: COMPARATOR
Intervention: Female athletes during lateral drop landing
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lateral drop landing
Number of subjects: 22

Group type: COMPARATOR
Intervention: Female athletes during medial drop task
Number of subjects: 22
Study: 12957528

Group type: EXPERIMENTAL
Intervention: Intraluminal aortoplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical aortic resection
Number of subjects: 0
Study: 10683714

Group type: EXPERIMENTAL
Intervention: 1% solution of Citrus limon and Cydonia oblongata
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3% solution of Citrus limon and Cydonia oblongata
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 18
Study: 8973432

Group type: EXPERIMENTAL
Intervention: Solar treatment (water left in full sunlight)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (water kept indoors in the shade)
Number of subjects: 206
Study: 1317657

Group type: EXPERIMENTAL
Intervention: LMWH 10,000 U pre-HD (Group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LMWH 5000 U pre-HD (Group B)
Number of subjects: 29

Group type: COMPARATOR
Intervention: LMWH 5000 U pre-HD (Group C)
Number of subjects: 29

Group type: COMPARATOR
Intervention: H (Group AII)
Number of subjects: 29

Group type: COMPARATOR
Intervention: L (Group BII)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LMWH (all groups)
Number of subjects: 29
Study: 6376480

Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Haloperidol (5 mg)
Number of subjects: 27
Study: 30871628

Group type: EXPERIMENTAL
Intervention: Maintenance rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional rituximab (non-maintenance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab (induction therapy)
Number of subjects: 0
Study: 29601278

Group type: EXPERIMENTAL
Intervention: Hypnotherapy with posthypnotic suggestions delivered once a week over 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 25648736

Group type: EXPERIMENTAL
Intervention: Low-fat high-carbohydrate diet
Number of subjects: 102

Group type: COMPARATOR
Intervention: Moderate-fat diet
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Low-calorie low-fat high-carbohydrate diet
Number of subjects: 102
Study: 24692301

Group type: EXPERIMENTAL
Intervention: Triple DMARD therapy + IM glucocorticoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple DMARD therapy + oral glucocorticoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTX treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCQ treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTXGlu2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTXGlu3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTXGlu4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTXGlu5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total MTXGlu
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Validation cohort
Number of subjects: 0
Study: 22974280

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily for 18 weeks
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo for 18 weeks, then glimepiride 1-4 mg once daily for 34 weeks
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Linagliptin during 34-week extension
Number of subjects: 227

Group type: COMPARATOR
Intervention: Glimepiride during 34-week extension
Number of subjects: 227
Study: 20179613

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal clipping
Number of subjects: 30

Group type: COMPARATOR
Intervention: No clipping (control)
Number of subjects: 30
Study: 18071098

Group type: EXPERIMENTAL
Intervention: Randomized psychosocial intervention study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants in the psychosocial intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 0
Study: 15597185

Group type: EXPERIMENTAL
Intervention: Foreground elements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Background elements
Number of subjects: 0
Study: 11984518

Group type: EXPERIMENTAL
Intervention: Real exercise program (head-raising exercise) for 6 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham exercise
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Real exercise program (after crossover from sham)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Entire group (27 patients) before and after exercise
Number of subjects: 27
Study: 9860151

Group type: EXPERIMENTAL
Intervention: Sparfloxacin with ammonium chloride (acidification)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sparfloxacin with sodium bicarbonate (alkalinization)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no acidification or alkalinization)
Number of subjects: 9
Study: 7896655

Group type: EXPERIMENTAL
Intervention: Naltrexone, 1.0 mg/kg, daily
Number of subjects: 13
Study: 2654391

Group type: EXPERIMENTAL
Intervention: OM-8980
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 199128

Group type: EXPERIMENTAL
Intervention: Intravenous injection of naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 6939007

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0